Your browser doesn't support javascript.
loading
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
Sunguc, Ceren; Hawkins, Michael M; Winter, David L; Dudley, Isabelle M; Heymer, Emma J; Teepen, Jop C; Allodji, Rodrigue S; Belle, Fabiën N; Bagnasco, Francesca; Byrne, Julianne; Bárdi, Edit; Ronckers, Cécile M; Haddy, Nadia; Gudmundsdottir, Thorgerdur; Garwicz, Stanislaw; Jankovic, Momcilo; van der Pal, Helena J H; Mazic, Maja Cesen; Schindera, Christina; Grabow, Desiree; Maule, Milena M; Kaatsch, Peter; Kaiser, Melanie; Fresneau, Brice; Michel, Gisela; Skinner, Roderick; Wiebe, Thomas; Sacerdote, Carlotta; Jakab, Zsuzsanna; Gunnes, Maria Winther; Terenziani, Monica; Winther, Jeanette F; Lähteenmäki, Päivi M; Zaletel, Lorna Zadravec; Kuehni, Claudia E; Kremer, Leontien C; Haupt, Riccardo; de Vathaire, Florent; Hjorth, Lars; Reulen, Raoul C.
Affiliation
  • Sunguc C; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Hawkins MM; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Winter DL; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Dudley IM; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Heymer EJ; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Teepen JC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Allodji RS; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM U1018, University Paris Saclay, Gustave Roussy, Villejuif, France.
  • Belle FN; Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Bagnasco F; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
  • Byrne J; IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Bárdi E; Boyne Research Institute, c/o no. 1, The Maples, Bettystown, Co Meath, A92 C635, Ireland.
  • Ronckers CM; St Anna Children's Hospital, Vienna, Austria and Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.
  • Haddy N; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Gudmundsdottir T; Department of Health Services Research, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
  • Garwicz S; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM U1018, University Paris Saclay, Gustave Roussy, Villejuif, France.
  • Jankovic M; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.
  • van der Pal HJH; Children's Hospital, Landspitali University Hospital, Reykjavik, Iceland.
  • Mazic MC; Department of Clinical Sciences Lund, Paediatrics, Skane University Hospital, Lund University, Lund, Sweden.
  • Schindera C; Pediatric Clinic, University of Milano-Bicocca, Hospital San Gerardo, Via Donizetti, 33, Monza, Italy.
  • Grabow D; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Maule MM; University Children's Hospital Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Kaatsch P; Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Kaiser M; Division of Pediatric Oncology/Haematology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
  • Fresneau B; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes-Gutenberg University Mainz, Mainz, Germany.
  • Michel G; Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
  • Skinner R; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes-Gutenberg University Mainz, Mainz, Germany.
  • Wiebe T; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes-Gutenberg University Mainz, Mainz, Germany.
  • Sacerdote C; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM U1018, University Paris Saclay, Gustave Roussy, Villejuif, France.
  • Jakab Z; Department of Children and Adolescents Oncology, Gustave Roussy, F-94805, Villejuif, France.
  • Gunnes MW; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
  • Terenziani M; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
  • Winther JF; Department of Clinical Sciences Lund, Paediatrics, Skane University Hospital, Lund University, Lund, Sweden.
  • Lähteenmäki PM; Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
  • Zaletel LZ; Hungarian Childhood Cancer Registry, 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
  • Kuehni CE; Division of Paediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Kremer LC; Department of Registration, Cancer Registry of Norway, Oslo, Norway.
  • Haupt R; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • de Vathaire F; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.
  • Hjorth L; Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark.
  • Reulen RC; Department of Pediatrics and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland.
Br J Cancer ; 128(1): 80-90, 2023 01.
Article in En | MEDLINE | ID: mdl-36319851
ABSTRACT

BACKGROUND:

Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks.

METHODS:

The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.

RESULTS:

One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI 4.4-5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI 14.6-25.2) followed by bone sarcoma (SIR = 6.4, 95% CI 3.7-11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI 3.9-9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI 3.0-8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI 25.3-44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI 43.6-100.5) and leukaemia (SIR = 50.5, 95% CI 36.1-70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI 10.6-23.7).

CONCLUSIONS:

Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Bone Neoplasms / Hodgkin Disease / Mouth Neoplasms / Leukemia / Neoplasms, Second Primary Type of study: Etiology_studies / Risk_factors_studies Limits: Adolescent / Humans Country/Region as subject: Europa Language: En Journal: Br J Cancer Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Bone Neoplasms / Hodgkin Disease / Mouth Neoplasms / Leukemia / Neoplasms, Second Primary Type of study: Etiology_studies / Risk_factors_studies Limits: Adolescent / Humans Country/Region as subject: Europa Language: En Journal: Br J Cancer Year: 2023 Document type: Article Affiliation country: